The progress that keeps on progressing. It’s amazing to see what has been achieved in such a short time , but even more exciting to think what the future holds for our patients #lungcancer
It's always exciting to share some #goodnews. We've published an article in the IASLC Lung Cancer News that looks at the stunning progress achieved in #lungcancer treatment over the last decade. Enjoy and #HappyFriday! #LCSM#FridayFeeling https://t.co/ZkbPEB5rTu
Here they are, working from home to protect their patients. Their commitment and perseverance to push through during these difficult times, with patient care as their first priority is like no other. Thank you for always putting your patients first. #stayhome@OncNl
Access to oral cancer drugs in🇨🇦is inconsistent across provinces, and Atlantic Canada often last. So good news today: osimertinib for EGFR+ NSCLC approved in 1st + 2nd line in Newfoundland/Labrador https://t.co/3zRxKi6fQh (#29) @reneelester16@LungCancer_Can#IDeserveToLive
Good news today for patients with squamous NSCLC. @CADTH_ACMTS has reversed it's initial decision after input from @LungCancer_Can and others. Now pembrolizumab and chemo IS RECOMMENDED as 1L treatment! https://t.co/VsYSYRb5LS. Advocacy works. #IDeserveToLive#HopeUnites
We are BEYOND excited to be welcoming over 500 participants for Polka Dot Trot this Sunday! We are amazed at the support for this event! #impact#cancercare#righthere Find out more at https://t.co/JnYrX62ERi Thank you to our Presenting Sponsor @WeAreJohnson
From @CurrentOncology: "If the drug has been approved for funding in one province but not the other, one patient will receive it for free, while the other patient might have to remortgage their residence" https://t.co/unASLSx4Qr #CancerCannotWait
AMG 510 appears to be specific for mutated Kras with no/little apparent off target toxicity and more than 50% RR. The excitement continues! @iaslc#WCLC19#LCSM